| For: | Wang Z, Wu Q, Wang Q. Effect of celecoxib on improving depression: A systematic review and meta-analysis. World J Clin Cases 2022; 10(22): 7872-7882 [PMID: 36158469 DOI: 10.12998/wjcc.v10.i22.7872] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i22/7872.htm |
| Number | Citing Articles |
| 1 |
Luke Baxter, Nathan Utulu, Faith Utulu, Sarah Utulu, Lorraine Li, Rebecca Strawbridge, Timothy R. Powell, James Rucker. An umbrella review of inflammatory biomarkers and their relationship to treatment response in MDD. Neuroscience & Biobehavioral Reviews 2026; 188 doi: 10.1016/j.neubiorev.2026.106806
|
| 2 |
Anti-Inflammatory Effects of Antidepressant Treatments and the Use of Inflammatory Biomarkers in Major Depressive Disorder: A Narrative Review. Journal of Psychiatry and Brain Science 2026; 11(3) doi: 10.20900/jpbs.20260006
|
| 3 |
Marianela Evelyn Traetta, Adriano Maia Chaves Filho, Elizabeth Toyin Akinluyi, Marie-Ève Tremblay. Microglia. Advances in Neurobiology 2024; 37 doi: 10.1007/978-3-031-55529-9_26
|
| 4 |
Rui Sun, Meng-Yu Tang, Dan Yang, Yan-Yi Zhang, Yi-Heng Xu, Yong Qiao, Bin Yu, Shu-Xia Cao, Hao Wang, Hui-Qian Huang, Hong Zhang, Xiao-Ming Li, Hong Lian. C3aR in the medial prefrontal cortex modulates the susceptibility to LPS-induced depressive-like behaviors through glutamatergic neuronal excitability. Progress in Neurobiology 2024; 236 doi: 10.1016/j.pneurobio.2024.102614
|
| 5 |
Manit Srisurapanont, Chawisa Suradom, Sirijit Suttajit. Celecoxib adjunct to antidepressants for major depressive disorder: Systematic review and meta-analysis. Brain, Behavior, & Immunity - Health 2026; 55 doi: 10.1016/j.bbih.2026.101277
|
| 6 |
Shijin Wu, Xiaofa Gao, Yuyang Zhou, Zibo Lin, Chuting Chen, Jing Luo, Xiaoyun Liu, Liming Lin, Hongwei Shao, Song Liu. Inflammation in treatment-resistant depression: From mechanisms to therapeutics. Brain Research Bulletin 2026; 241 doi: 10.1016/j.brainresbull.2026.111953
|
| 7 |
Hui Zhao, Larissa Tao, Cheng Tang, Wa Cai, Weidong Shen. Do immune system and microbiome–gut–brain axis interactions associate with major depressive disorder?. Journal of Translational Medicine 2025; 23(1) doi: 10.1186/s12967-025-07176-w
|
| 8 |
Monika Dominiak, Adam Gędek, Michalina Sikorska, Paweł Mierzejewski, Marcin Wojnar, Anna Z. Antosik-Wójcińska. Acetylsalicylic Acid and Mood Disorders: A Systematic Review. Pharmaceuticals 2022; 16(1) doi: 10.3390/ph16010067
|
| 9 |
Yishu Yin, Ting Ju, Deyong Zeng, Fangyuan Duan, Yuanbing Zhu, Junlian Liu, Yongzhi Li, Weihong Lu. “Inflamed” depression: A review of the interactions between depression and inflammation and current anti-inflammatory strategies for depression. Pharmacological Research 2024; 207 doi: 10.1016/j.phrs.2024.107322
|
| 10 |
Urszula Bąk, Anna Krupa. Challenges and Opportunities for Celecoxib Repurposing. Pharmaceutical Research 2023; 40(10) doi: 10.1007/s11095-023-03571-4
|
| 11 |
Yu-qi Chen, Jun-rui Ye, Sha-sha Wang, Ye Peng, Run Zhou, Ruo-lan Yuan, Wen-fei Wang, Shi-feng Chu, Zhao Zhang, Nai-hong Chen. Esflurbiprofen exerts a fast-onset antidepressant effect by blocking SERT-nNOS interaction. Acta Pharmacologica Sinica 2026; 47(3) doi: 10.1038/s41401-025-01666-9
|
| 12 |
Mario Pinzi, Andrea Fagiolini, Despoina Koukouna, Giacomo Gualtieri, Maria Beatrice Rescalli, Caterina Pierini, Simone Pardossi, Benjamin Patrizio, Alessandro Cuomo. Inflammatory and Immune Biomarkers in Mood Disorders: From Mechanistic Pathways to Clinical Translation. Cells 2025; 14(19) doi: 10.3390/cells14191558
|
| 13 |
Adam Gędek, Zofia Szular, Anna Z. Antosik, Paweł Mierzejewski, Monika Dominiak. Celecoxib for Mood Disorders: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine 2023; 12(10) doi: 10.3390/jcm12103497
|
| 14 |
Ana Salomé Correia, Nuno Vale. Advancements Exploring Major Depressive Disorder: Insights on Oxidative Stress, Serotonin Metabolism, BDNF, HPA Axis Dysfunction, and Pharmacotherapy Advances. International Journal of Translational Medicine 2024; 4(1) doi: 10.3390/ijtm4010010
|
| 15 |
Mohsin Ali Khan, Zaw Ali Khan, Mohammad M Khan. Metabolic complications of psychotropic medications in psychiatric disorders: Emerging role of <i>de novo</i> lipogenesis and therapeutic consideration. World Journal of Psychiatry 2024; 14(6): 767-783 doi: 10.5498/wjp.v14.i6.767
|
| 16 |
Shivangini Singh, Anil Nischal, Anuradha Nischal, Satyendra Kumar Singh, Vipul Singh, Adarsh Tripathi. Exploring early add-on celecoxib treatment in OCD: Results from a preliminary randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology 2025; doi: 10.1177/02698811251389556
|
| 17 |
Xiao Feng, Min Jia, Meng Cai, Tong Zhu, Kenji Hashimoto, Jian-Jun Yang. Central-peripheral neuroimmune dynamics in psychological stress and depression: insights from current research. Molecular Psychiatry 2025; 30(10) doi: 10.1038/s41380-025-03085-y
|
| 18 |
Gauri Pandey, Mohsin Ali Khan, Zaw Ali Khan, Mohammad M Khan. Childhood insulin resistance and neural stem cell dysfunction in psychiatric disorders: Role of <i>de novo</i> lipogenesis and treatment perspectives. World Journal of Stem Cells 2025; 17(7): 106194 doi: 10.4252/wjsc.v17.i7.106194
|
| 19 |
Sahar Ansari, Hossein Sanjari Moghaddam, Fatemeh A. Basti, Mohammadreza Salehi, Shahin Akhondzadeh. Efficacy and safety of celecoxib monotherapy for treatment of moderate depressive symptoms following COVID-19 infection: A randomized, double-blind, placebo-controlled trial. Journal of Psychosomatic Research 2023; 174 doi: 10.1016/j.jpsychores.2023.111471
|
| 20 |
Evelien Van Assche, Christa Hohoff, Sophia M. Wissing, Lea Steinbach, Bernhard T. Baune. Response to immune-based augmentation treatment for depression: a potential role of immunosenescence. Neuroscience Applied 2026; 5 doi: 10.1016/j.nsa.2026.106986
|
| 21 |
Sergey K. Zyryanov, Elena A. Baybulatova. Current challenges for therapy of comorbid patients: a new look at celecoxib. A review. Terapevticheskii arkhiv 2024; 96(5) doi: 10.26442/00403660.2024.05.202769
|
| 22 |
Daniel Kinderlehrer. Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity. Neuropsychiatric Disease and Treatment 2025; doi: 10.2147/NDT.S500337
|
| 23 |
Kriti Sharma, Devendra Kumar, Nisha Chandna, Jitander K. Kapoor. Celecoxib Reimagined: Multifunctional Roles in Advanced Drug Delivery and Therapeutics. ChemistrySelect 2025; 10(31) doi: 10.1002/slct.202502652
|
| 24 |
A Halaris, A Sayed, M Hakimi, J Sinacore. Modulation of the inflammatory response exerts beneficial effects on anger in treatment-resistant bipolar depression. Journal of Affective Disorders Reports 2023; 13 doi: 10.1016/j.jadr.2023.100602
|
| 25 |
Sepideh Hajivalizadeh, Kimia Farahmand, Kimia Kazemzadeh, Ghazaleh Hajivalizadeh, Ahmad Shamabadi. Pharmacotherapeutic Management of Depression in Patients With Cancer: A Review of Mechanistic and Clinical Evidence. Cancer Reports 2026; 9(5) doi: 10.1002/cnr2.70587
|
| 26 |
Ashish Verma, Anmol Kumar, Satendra Chauhan, Nisha Sharma, Anuradha Kalani, Prakash Chandra Gupta. Interconnections of screen time with neuroinflammation. Molecular and Cellular Biochemistry 2025; 480(3) doi: 10.1007/s11010-024-05123-9
|
| 27 |
Xenia Gonda, Gianluca Serafini, Peter Dome. Fight the Fire: Association of Cytokine Genomic Markers and Suicidal Behavior May Pave the Way for Future Therapies. Journal of Personalized Medicine 2023; 13(7) doi: 10.3390/jpm13071078
|
| 28 |
Bárbara Dicarlo Costa Braga, Bruna Teixeira da Costa, Katiene Rodrigues Menezes de Azevedo. Tratamento anti-inflamatório na depressão: uma revisão sistemática. Debates em Psiquiatria 2024; 14 doi: 10.25118/2763-9037.2024.v14.1156
|
| 29 |
Erhan Kavakbasi, Emma Sampson, Natalie T. Mills, Hikaru Hori, Kathrin Schwarte, Christa Hohoff, K. Oliver Schubert, Scott R. Clark, Célia Fourrier, Bernhard T. Baune. Inflammation‐stratified augmentation of vortioxetine with celecoxib: Results from a double‐blind, randomized, placebo‐controlled trial in major depressive disorder. Journal of Neurochemistry 2024; 168(9) doi: 10.1111/jnc.15946
|
| 30 |
Cheng-gang Li, Lu-shan Xu, Liang Sun, Yu-hao Xu, Xiang Cao, Chen-chen Zhao, Sheng-nan Xia, Qing-xiu Zhang, Yun Xu. Xiangshao Granules Ameliorate Post-stroke Depression by Inhibiting Activation of Microglia and IDO1 Expression in Hippocampus and Prefrontal Cortex. Chinese Journal of Integrative Medicine 2025; 31(1) doi: 10.1007/s11655-024-3903-5
|
| 31 |
Irina A. Goldina, Evgeniya V. Markova, Maria A. Knyazheva, Ivan V. Savkin, Tamara V. Shushpanova, Olga S. Anikeeva. Contemporary approaches to the immunotherapy of depression. Reviews on Clinical Pharmacology and Drug Therapy 2025; 23(4) doi: 10.17816/RCF680652
|
| 32 |
Run Zhou, Ruolan Yuan, Junrui Ye, Shasha Wang, Yuqi Chen, Xiaofen Zhou, Shifeng Chu, Zhao Zhang, Naihong Chen. Trans-cinnamaldehyde alleviates IFN-α-induced depressive-like behaviors by restoring astrocytic Cx43 gap junction. International Immunopharmacology 2025; 167 doi: 10.1016/j.intimp.2025.115741
|
| 33 |
Marcel Bertsch-Gout, Anthony T. Reder, Royce Lee. Stress: Immunology and Inflammation. 2024; doi: 10.1016/B978-0-12-817558-3.00017-2
|
| 34 |
Bruna R. Kouba, Laura de Araujo Borba, Pedro Borges de Souza, Joana Gil-Mohapel, Ana Lúcia S. Rodrigues. Role of Inflammatory Mechanisms in Major Depressive Disorder: From Etiology to Potential Pharmacological Targets. Cells 2024; 13(5) doi: 10.3390/cells13050423
|
| 35 |
Anna Łysik, Katarzyna Logoń, Aleksandra Szczygieł, Julia Wołoszczak, Martyna Wrześniewska, Jerzy Leszek. Innovative approaches in the treatment-resistant depression: exploring different therapeutic pathways. GeroScience 2025; 47(4) doi: 10.1007/s11357-025-01615-8
|
| 36 |
Bartosz Adam Frycz, Magdalena Dutsch-Wicherek, Olga Płaza, Agata Szulc, Monika Bijata, Jakub Wlodarczyk, Joanna Dzwonek. The synaptic triad in depression: how stress-related pathways converge on BDNF, NMDA receptor, and MMP-9. Pharmacological Reports 2026; 78(2) doi: 10.1007/s43440-026-00827-9
|